DNLI:NSD-Denali Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 21.45

Change

0.00 (0.00)%

Market Cap

USD 3.35B

Volume

2.81M

Analyst Target

USD 29.18
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.00 (+2.01%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+13.28 (+1.89%)

USD 84.94B
ARGX argenx NV ADR

+4.50 (+0.72%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-3.18 (-1.30%)

USD 31.66B
BGNE BeiGene Ltd

+1.20 (+0.68%)

USD 20.24B
UTHR United Therapeutics Corporatio..

+4.07 (+1.13%)

USD 16.18B
MRNA Moderna Inc

+0.20 (+0.51%)

USD 16.10B
RPRX Royalty Pharma Plc

+0.33 (+1.32%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.80 (+4.48%)

USD 13.67B
INCY Incyte Corporation

+1.00 (+1.45%)

USD 13.52B

ETFs Containing DNLI

SBIO ALPS Medical Breakthrough.. 2.28 % 0.50 %

-0.01 (-0.32%)

USD 0.11B
XSU:CA iShares US Small Cap (CAD.. 0.00 % 0.36 %

-0.14 (-0.32%)

CAD 0.84B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.05% 67% D+ 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.05% 67% D+ 47% F
Trailing 12 Months  
Capital Gain -2.32% 64% D 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.32% 64% D 43% F
Trailing 5 Years  
Capital Gain 10.40% 80% B- 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.40% 79% B- 51% F
Average Annual (5 Year Horizon)  
Capital Gain 14.78% 61% D- 68% D+
Dividend Return 14.78% 61% D- 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 88.51% 41% F 24% F
Risk Adjusted Return 16.70% 68% D+ 49% F
Market Capitalization 3.35B 92% A 84% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector